51³Ô¹ÏÍø

About Us
Self Reflected by Greg Dunn

We want to improve the lives of people living with mental health conditions by developing effective, rapid-acting and accessible medicines.

51³Ô¹ÏÍø combines cutting-edge science with deep drug development expertise to accelerate the research and clinical development of novel and effective treatments for people in need.

Within our pipeline, we are focusing on the potential of next-generation psychedelic-based compounds that can be administered in a short clinic visit, are well-tolerated, and can deliver rapid, robust, and lasting treatment effects in order to improve the lives of those living with mental health disorders.

More about
Our Work
Our Team
Our
Story

For our founders, Lady Amanda Feilding and Cosmo Feilding Mellen, research into the potential of psychedelic compounds has been a lifelong and intergenerational vocation.

Amanda has dedicated over 50 years to the scientific exploration of these compounds. She is the Founder and Director of the Beckley Foundation, a non-profit NGO established in 1998 to accelerate scientific research into psychoactive substances. In the last 20 years, the Beckley Foundation has supported, among other studies, the world’s first LSD brain imaging study and the first clinical trial into psilocybin-assisted psychotherapy for Treatment Resistant Depression (TRD).

51³Ô¹ÏÍø was created in 2019 to build upon the Foundation’s work by developing effective, rapid-acting and accessible psychedelic-based medicines for patients in need. 

Since then, the team has:

  • Developed two novel synthetic compounds that are now in Phase II clinical studies
  • Received the U.S FDA’s first Investigational New Drug (IND) approval for a Phase IIb study of a short-acting psychedelic compound
  • Designed a library of new chemical entities (NCEs) that are currently in preclinical development
  • Partnered with leading academic and patient-focused organisations like Imperial College London and PsyPAN to drive forward research and participant support
  • Built an international team of experienced and passionate drug development experts
Our
Values

Patient-Focused

We put patients at the centre of everything we do and we constantly seek opportunities to meaningfully support and involve them in our work.

Science-Driven

We understand the importance of scientific rigour in our decision-making, and we strive to use data to identify new options for innovation.

Ethical

We hold ourselves accountable to adhere to high standards in all of our activities.

Collaborative

We strive to achieve our mission through internal and external partnerships and are committed to maintaining a culture of continuous learning.

Innovative

We encourage our team to think differently and iterate quickly so we can move towards our mission with urgency.

Our
Investors

Other investors include investment entities (e.g. funds and family offices) and individuals.